1. Home
  2. MDXH vs ASMB Comparison

MDXH vs ASMB Comparison

Compare MDXH & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDXH
  • ASMB
  • Stock Information
  • Founded
  • MDXH 2003
  • ASMB 2005
  • Country
  • MDXH Belgium
  • ASMB United States
  • Employees
  • MDXH N/A
  • ASMB N/A
  • Industry
  • MDXH
  • ASMB Biotechnology: Pharmaceutical Preparations
  • Sector
  • MDXH
  • ASMB Health Care
  • Exchange
  • MDXH Nasdaq
  • ASMB Nasdaq
  • Market Cap
  • MDXH 203.4M
  • ASMB 225.9M
  • IPO Year
  • MDXH 2021
  • ASMB 2010
  • Fundamental
  • Price
  • MDXH $3.28
  • ASMB $37.04
  • Analyst Decision
  • MDXH Strong Buy
  • ASMB Strong Buy
  • Analyst Count
  • MDXH 3
  • ASMB 6
  • Target Price
  • MDXH $7.67
  • ASMB $43.40
  • AVG Volume (30 Days)
  • MDXH 333.0K
  • ASMB 131.9K
  • Earning Date
  • MDXH 11-12-2025
  • ASMB 11-10-2025
  • Dividend Yield
  • MDXH N/A
  • ASMB N/A
  • EPS Growth
  • MDXH N/A
  • ASMB N/A
  • EPS
  • MDXH N/A
  • ASMB N/A
  • Revenue
  • MDXH $103,069,000.00
  • ASMB $37,191,000.00
  • Revenue This Year
  • MDXH $24.78
  • ASMB $14.29
  • Revenue Next Year
  • MDXH $21.20
  • ASMB N/A
  • P/E Ratio
  • MDXH N/A
  • ASMB N/A
  • Revenue Growth
  • MDXH 21.68
  • ASMB 31.30
  • 52 Week Low
  • MDXH $1.35
  • ASMB $7.75
  • 52 Week High
  • MDXH $5.33
  • ASMB $39.71
  • Technical
  • Relative Strength Index (RSI)
  • MDXH 26.74
  • ASMB 69.38
  • Support Level
  • MDXH $2.75
  • ASMB $35.00
  • Resistance Level
  • MDXH $4.98
  • ASMB $37.71
  • Average True Range (ATR)
  • MDXH 0.28
  • ASMB 2.01
  • MACD
  • MDXH -0.17
  • ASMB 0.31
  • Stochastic Oscillator
  • MDXH 23.45
  • ASMB 70.94

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Share on Social Networks: